Loading clinical trials...
Loading clinical trials...
An Open-Label Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 for 40 Weeks in the Treatment of Moderate to Severe Facial Papulopustular Rosacea (Study FX2016-13)
Conditions
Interventions
FMX103 1.5%
Locations
79
United States
Foamix Investigational Site # 207
Glendale, Arizona, United States
Foamix Investigational Site # 202
Hot Springs, Arkansas, United States
Foamix Investigational Site # 222
Rogers, Arkansas, United States
Foamix Investigational Site # 127
Fremont, California, United States
Foamix Investigational Site # 226
Los Angeles, California, United States
Foamix Investigational Site # 220
Murrieta, California, United States
Start Date
September 5, 2017
Primary Completion Date
January 3, 2019
Completion Date
January 15, 2019
Last Updated
January 18, 2022
NCT01872715
NCT01494467
NCT04608500
NCT02393937
NCT00855595
NCT03263273
Lead Sponsor
Vyne Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions